Active Studies
Browse a listing of research studies currently underway and led by Mesulam Center investigators.
Answer some questions to see if our research may be a good fit for you.
Alzheimer’s Disease Neuroimaging Initiative 3
The overall goal of Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3) is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as the pathology evolves from normal aging through very mild symptoms, to mild cognitive impairment (MCI), to dementia.
Alzheimer's Disease Research Center (ADRC)
The purpose of the Northwestern Alzheimer’s Disease Research Center (NU ADRC) research registry is to 1) provide state-of-the-art care to patients with mild cognitive impairment, Alzheimer’s disease and related disorders, and to 2) support clinical and basic research on memory and aging collecting, storing, and disseminating clinical data, brain imaging, and biological samples from research participants to collaborators.
ALLFTD Study
The overall goal of ALLFTD is to prepare a cohort of individuals with most varieties of frontotemporal lobar degeneration (FTLD) for future studies including clinical trials. FTLD is a neurological disease that causes Frontotemporal Dementia (FTD) syndromes including Primary Progressive Aphasia (PPA) and Behavioral Variant Frontotemporal Dementia (bvFTD), among others.
The AHEAD Study
An abnormal form of a protein called “amyloid” builds up in the brains of people with Alzheimer’s disease (AD), but not every person with amyloid build up will develop memory problems or AD dementia. The purpose of this study is to determine if an investigational drug reduces the risk of developing AD dementia.
Language in Primary Progressive Aphasia
The Language in Primary Progressive Aphasia (PPA) aims to better understand progression in PPA and its link to brain changes, increase awareness of PPA, and identify biomarkers leading to earlier diagnosis and treatment. Participants are asked to undergo tests of language and thinking abilities and have brain scans every two years.
Longitudinal Early-onset Alzheimer's Disease Study (LEADS)
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset Alzheimer's disease (EOAD). Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across two cohorts: (1) individuals with EOAD and (2) cognitively normal (CN) control participants.
Alzheimer's Prevention Study (TRC-PAD)
This is an observational study that advances Alzheimer’s research by matching healthy people with clinical trials to prevent Alzheimer’s disease. Participants who meet certain criteria and are identified as being at potential increased risk for future memory loss caused by Alzheimer’s disease are eligible. The purpose of this study is to create a trial-ready cohort (TRC) to further dementia research.